preferred drug

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Bio & Pharma Celltrion expands footprint in Latin America with flagship oncology drugs

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Real estate Deloitte Anjin to lead sale of Four Points by Sheraton Josun, Myeongdong

IGIS Asset Management Co., a leading South Korean real estate investment firm, has chosen Deloitte Anjin LLC as its lead manager to sell Four Points...

Bio & Pharma Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Bio & Pharma SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Bio & Pharma Chong Kun Dang to build new plant for foray into biologics market

Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Real estate Koramco REITS chosen preferred buyer of Crescendo Building in Seoul

Koramco REITs Management & Trust Co., a leading South Korean real estate firm, has been chosen as the preferred negotiator to buy the Crescendo ...

Bio & Pharma Lotte Biologics eyes first ADC CDMO order in 2025

SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...

IPOs Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

Bio & Pharma SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US

South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...

Bio & Pharma Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

Bio & Pharma Boryung, Lotus Pharma signs CDMO deal on anticancer injection

South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...

Bio & Pharma SK Biopharm submits NDA of epilepsy drug to China

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

Real estate GIC to pick preferred bidder in $1.1 bn Seoul landmark building sale

Singapore’s GIC Private Ltd., the world’s sixth-largest sovereign wealth fund, is set to select a preferred bidder for the sale of a lan...

Batteries Korea Zinc, Hanwha to co-work on Austrailian BESS project

Korea Zinc Inc., the world’s top lead and zinc smelter, said on Tuesday its Australian subsidiary Ark Energy selected Hanwha Corp. as the pref...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Hanmi Pharma to move up launch of anti-obesity drug

South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...

Bio & Pharma Samsung Biologics wins $668 million CDMO deal with European pharma

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...

Logistics Korean logistics companies expand overseas businesses

South Korea’s logistics companies such as local industry leader CJ Logistics Corp. are expanding their overseas operations to take advantage o...

Aerospace & Defense Korea’s LIG Nex1 to export unmanned surface vessel

GUMI, North Gyeongsang Province — South Korean defense maker LIG Nex1 Co. aims to export its unmanned surface vessel (USV) under development a...

Corporate strategy Apparel maker Hansae sets sights on auto parts business as growth driver

HO CHI MINH CITY – South Korean apparel maker Hansae Yes24 Group has set its sights on the auto parts business as a new growth driver to diver...

Bio & Pharma Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Business & Politics Korail to join Manila railway maintenance project

South Korea's state-run railway company Korea Railroad Corporation (Korail) said on Monday that it participates in the operation and maintenance (O&...

Mergers & Acquisitions IMM consortium picked as preferred bidder for Ecorbit

A consortium of IMM Private Equity and IMM Investment has moved a step closer to owning South Korea’s No. 1 landfill company Ecorbit Co. after...

Leadership & Management Hanwha’s Kim Dong-seon to raise his stake in Galleria to 19.86%

Kim Dong-seon, vice president of South Korea’s Hanwha Galleria Corp. and the third son of Hanwha Group Chairman Kim Seung-yeon, plans to buy a...

Bio & Pharma Yuhan’s lung cancer drug clears FDA hurdle for global debut

A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...

Mergers & Acquisitions Hansae Yes24 moves closer to acquiring GM supplier Erae AMS

Hansae Yes24 Holdings Co., the holding company of South Korea’s leading apparel original equipment manufacturer (OEM) Hansae Co., has moved a ...

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...